Revvity (RVTY) Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $711 million, reflecting 3% organic growth; pro forma revenue (excluding the immunodiagnostics business in China) was $687 million, equating to 6% organic growth.

Adjusted Operating Margin: 23.6%, exceeding the 23% outlook; pro forma adjusted operating margin was 24%.

Adjusted Earnings Per Share (EPS): $1.06, above the guidance range of $1.02 to $1.04.

Free Cash Flow: $115 million, with a robust conversion rate of 97% of adjusted net income.

Debt Metrics: Net debt to adjusted EBITDA ratio of 2.8x, with 100% of debt being fixed rate.

2Strategic Updates and Business Highlights

Divestiture of Immunodiagnostics Business: Revvity plans to divest its immunodiagnostics business in China, which represented about 6% of total revenue last year. This strategic move aims to focus resources on higher-return areas and is expected to enhance overall financial performance.

Growth in Life Sciences: The Life Sciences segment showed solid performance, with reagents growing above overall performance and a positive outlook for continued growth in 2026.

Software Innovations: Revvity introduced several new software platforms, including Xynthetica and BioDesign, aimed at enhancing AI-driven research capabilities.

Market Conditions: Modest improvements in pharma and biotech spending were noted, with positive growth in academic and government sectors.

3Forward Guidance and Outlook

2026 Guidance:

Organic growth is now expected to be in the range of 3% to 4%, reflecting the exclusion of the immunodiagnostics business.

Adjusted operating margins are projected at 28.4%, up 40 basis points from previous guidance.

Adjusted EPS is now forecasted at $5.20 to $5.30, reflecting a $0.15 reduction due to the divestiture.

Q2 2026 Expectations: Pro forma organic growth is anticipated to be between 2% to 3%, with total revenue expected to range from $699 million to $707 million.

4Bad News, Challenges, or Points of Concern

China Market Challenges: The immunodiagnostics business in China faced persistent headwinds due to policy-induced issues affecting demand and pricing. The divestiture reflects ongoing challenges in this market.

Cautious Outlook: Despite positive trends, Revvity remains prudent in its forward-looking assumptions due to potential volatility in customer spending and regulatory changes.

Software Business Volatility: The software segment is expected to face tougher comparisons in Q2, with anticipated declines of approximately 20% in organic growth.

5Notable Q&A Insights

Customer Engagement: Strong engagement and excitement around new software offerings were highlighted, particularly in partnerships with major pharma companies.

Reagents Business Stability: There are signs of improvement in the reagents business, with positive mid-single-digit growth noted, indicating a potential recovery in demand.

Future M&A Activity: Revvity remains open to acquisitions but is currently focused on share buybacks, indicating a strategic shift towards optimizing capital allocation.

Operational Efficiency: Cost efficiency initiatives are on track to enhance margins, with expectations for significant benefits starting in the second half of 2026. Overall, Revvity's Q1 2026 results reflect a strong start to the year, driven by strategic divestitures and growth in key segments, while also navigating challenges in specific markets and maintaining a cautious outlook for the remainder of the year.